Form 4: Unicycive Therapeutics Director Gaurav Aggarwal Reports Conversion of Preferred Stock and Resulting Common Stock Ownership

Director Gaurav Aggarwal reports a transaction involving the conversion of Series A-2 Prime Preferred Stock into common stock and adjustments to beneficial ownership.

Summary

• On February 18, 2025, Gaurav Aggarwal, a director of Unicycive Therapeutics, Inc., reported a transaction involving Series A-2 Prime Preferred Stock.
• Aggarwal converted 686 shares of Series A-2 Prime Preferred Stock into 1,400,000 shares of Common Stock.
• The conversion price was $0.49 per share, based on the Original Per Share Price of $1,000.
• Following the transaction, Aggarwal indirectly owns 11,370,152 shares of Common Stock through Vivo Opportunity Fund Holdings L.P.
• Aggarwal disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: This is a neutral report of a stock conversion. It doesn't inherently indicate positive or negative sentiment.

Management Comments

• The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Industry Context

Form 4 filings are standard practice for company insiders (directors, officers, and principal stockholders) to report transactions in their company's stock, providing transparency to the market.

Stakeholder Impact

• The conversion of preferred stock to common stock could potentially dilute existing shareholders' equity.

Key Dates

Keywords

Form 4, Beneficial Ownership, Unicycive Therapeutics, Aggarwal, Series A-2 Prime Preferred Stock, Common Stock, Conversion, Director, UNCY, Vivo Opportunity Fund